News Search Results
Sep 28, 2026, 06:30 ET Jaypirca® (pirtobrutinib) Approved in China for a New Indication in Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) Across All Lines of Therapy
data from the global Phase 3 BRUIN CLL-313 and BRUIN CLL-314 clinical trials. BRUIN CLL-313 is the first prospective, randomized Phase 3 study to examine the efficacy and safety of a non-covalent BTK inhibitor in patients with treatment-naïve CLL/SLL. In BRUIN CLL-313, the study demonstrated a statistically
More news about: Innovent Biologics
Sep 24, 2026, 07:24 ET ViferaXS wirbt 12 Millionen Euro ein, um Phase-II-Studie zur chronischen lymphatischen Leukämie voranzutreiben und seine onkologische Pipeline auszubauen
Beteiligung privater InvestorenMit den Erlösen werden eine Phase-II-Studie mit CLLTAXS01 bei chronischer lymphatischer Leukämie (CLL) sowie die bevorstehenden Auswertungen der Phase-I-Studien bei akuter myeloischer Leukämie (AML) und fibrolamellärem Karzinom (FLC) finanziert.
More news about: ViferaXS GmbH
Sep 23, 2026, 08:15 ET ViferaXS Raises €12 Million to Advance Phase II Trial in Chronic Lymphocytic Leukemia and Expand Its Oncology Pipeline
Huma, with participation from private investorsProceeds fund a Phase II trial of CLLTAXS01 in chronic lymphocytic leukemia (CLL), plus upcoming Phase I read-outs in acute myeloid leukemia (AML) and fibrolamellar carcinoma (FLC)TÜBINGEN,
More news about: ViferaXS GmbH
Sep 23, 2026, 02:15 ET ViferaXS Raises €12 Million to Advance Phase II Trial in Chronic Lymphocytic Leukemia and Expand Its Oncology Pipeline
Huma, with participation from private investorsProceeds fund a Phase II trial of CLLTAXS01 in chronic lymphocytic leukemia (CLL), plus upcoming Phase I read-outs in acute myeloid leukemia (AML) and fibrolamellar carcinoma (FLC)
More news about: ViferaXS GmbH
Sep 09, 2026, 10:31 ET Waldenström Macroglobulinemia Market to Gain Momentum During the Forecast Period (2026-2036) Due to Launch of Novel Drug Classes Including BTK Degraders, Non-covalent BTKi, BCL-2 Inhibitors, and Targeted Radiotherapeutics | DelveInsight
CNS-penetrating small-molecule degrader targeting Bruton's tyrosine kinase (BTK), currently under investigation for the treatment of chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma (NHL), and Waldenström macroglobulinemia (WM).The anticipated launch of these emerging therapies are poised to transform
More news about: DelveInsight Business Research, LLP
Aug 19, 2026, 08:32 ET Hematogenix's MM MRD Assay Underpins FDA Accelerated Approval of Bristol Myers Squibb's ZENBEXUS™, the First Approved CELMoD Therapy for Multiple Myeloma
pathways in multiple myeloma, a use case for which specialized, standardized assay methodology is essential. Hematogenix's NGF MRD platform for MM, AML and CLL is designed to meet the sensitivity, reproducibility, and regulatory-grade standards required for these registrational endpoints across sponsors' global
More news about: Hematogenix
Aug 18, 2026, 20:15 ET CARsgen Therapeutics Announces 2026 Interim Results
the EHA in June 2026.In addition, multiple products against different targets are currently under development: CT1390B against CLL1 for AML; KJ-C2526 against NKG2DL for AML, other malignancies and senescence; KJ-C2527 against Claudin18.2 for G/GEJA, etc.; KJ-C2630 against GPC3 for
More news about: CARsgen Therapeutics
Aug 13, 2026, 08:00 ET Curis, Inc. Announces Pricing of $5.6 Million Public Offering
relapsed/refractory primary central nervous system lymphoma (PCNSL) and in the TakeAim CLL Phase 2 study (CA-4948-203) of emavusertib in combination with the BTK inhibitor, zanubrutinib, in chronic lymphocytic leukemia (CLL). The Company's monotherapy and combination studies in acute myeloid leukemia (AML)
More news about: Curis, Inc.
Aug 12, 2026, 14:28 ET HSBC HOLDINGS PLC ANNOUNCES PRICING TERMS OF ITS TENDER OFFERS FOR FOUR SERIES OF NOTES
N/AUST 3.375% due September 15, 2027 (CUSIP 91282CLL3) 4.109 %
More news about: HSBC Holdings plc
Aug 06, 2026, 07:00 ET HSBC HOLDINGS PLC ANNOUNCES INCREASE OF (A) THE MAXIMUM TENDER AMOUNT OF ITS TENDER OFFERS FOR FOUR SERIES OF NOTES AND (B) THE MAY 2028 NOTES SUB-CAP IN RESPECT OF THE MAY 2028 NOTES
UST 3.375% due September 15, 2027 (CUSIP 91282CLL3) +20 basis points
More news about: HSBC Holdings plc
Aug 05, 2026, 06:45 ET Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress
Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy (
More news about: Eli Lilly and Company
Aug 04, 2026, 21:57 ET HSBC HOLDINGS PLC ANNOUNCES TENDER OFFERS FOR FOUR SERIES OF NOTES
UST 3.375% due September 15, 2027 (CUSIP 91282CLL3) +20 basis points('bps')
More news about: HSBC Holdings plc
Jul 31, 2026, 07:47 ET AbbVie Reports Second-Quarter 2026 Financial Results
for the treatment of adult patients with previously untreated chronic lymphocytic leukemia (CLL). The authorization provides an all-oral, fixed-duration, chemotherapy-free treatment option for patients with CLL and supports the potential for time off treatment. The expanded label is supported by data
More news about: AbbVie
Jul 30, 2026, 08:00 ET Curis Doses First Five Patients in TakeAim CLL Study
for enrollment in the TakeAim CLL study and 10 patients had been consented in that study. Today, Curis is announcing that it has achieved the previously stated goal of dosing the first five patients in the TakeAim CLL study and reaffirmed its expectation to report initial CLL data in 5-10 patients in December
More news about: Curis, Inc.
Jul 22, 2026, 10:31 ET CAR T-Cell Therapy for Non-Hodgkin Lymphoma Market Set for Robust Growth at a CAGR of ~7% Through 2036, Driven by Expanding Indications and Clinical Adoption | DelveInsight
(DLBCL), Follicular Lymphoma (FL), Primary Mediastinal Large B-cell Lymphoma (PMBCL), Marginal Zone Lymphoma (MZL), and Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL). Increasing utilization is being driven by the significant unmet need among relapsed or refractory patients,
More news about: DelveInsight Business Research, LLP
Jul 22, 2026, 07:00 ET Curis Announces Positive Emavusertib Update
the strong interest among clinical sites and key opinion leaders in our TakeAim CLL study that has enabled us to exceed expectations for site activation and enrollment."About PCNSL and CLLIn PCNSL and CLL, disease is driven by NF-kB dysregulation, which is in turn driven by two biologic
More news about: Curis, Inc.
Jul 06, 2026, 09:30 ET Curis Consents First Six Patients in TakeAim CLL Study
clinical sites had opened for enrollment in the TakeAim CLL study. Today, Curis is announcing that it has consented the first six patients in that study – and reaffirmed its guidance for the dosing of five CLL patients by the end of July 2026, with initial CLL data expected in December 2026."We are encouraged
More news about: Curis, Inc.
Jun 26, 2026, 09:42 ET Curis Announces Eleven Active Clinical Sites in TakeAim CLL Study, Reaffirms Patient Dosing Guidance, and Reports Stockholder Approval of Reverse Stock Split
TakeAim CLL UpdateEleven clinical sites are now open for enrollment in the TakeAim CLL study, reflecting strong investigator interest in the combination of emavusertib and zanubrutinib as a strategy to enable dual blockade of NF-kB, a key driver of CLL disease. The Company reaffirmed
More news about: Curis, Inc.
Jun 26, 2026, 07:16 ET Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy
for approval for adult patients with CLL, with a decision expected in the second half of 2026.About BRUIN CLL-313 BRUIN CLL-313 is a Phase 3, global, randomized, open-label study of pirtobrutinib versus chemoimmunotherapy (BR) in people with CLL/SLL without 17p deletions who have
More news about: Eli Lilly and Company
Jun 24, 2026, 07:00 ET Blood Cancer United and BeOne Medicines Announce Expanded Partnership to Advance Patient Support and Community for People Impacted by Blood Cancer
resources:Expert-led educational webcasts and resources for people living with blood cancers such as chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL) and non-Hodgkin lymphoma (NHL)The Clinical Trial Support Center (CTSC), which offers personalized guidance to help
More news about: BLOOD CANCER UNITED, INC.
Jun 17, 2026, 08:05 ET Lymphoma Research Foundation Awards 24 New Scientific Research Grants
ChicagoAnli Zhang, Ph.D., The University of Texas Southwestern Medical Center"This year's grant class represents the rising stars in lymphoma and CLL research," said Andrew Evens, DO, MBA, MSc, Deputy Director for Clinical Services and Chief Physician Officer, Rutgers Cancer Institute, and Chair of
More news about: Lymphoma Research Foundation
Jun 16, 2026, 08:00 ET 2026 Tang Prize in Biopharmaceutical Science Awarded to Three Pioneers of Cellular Immunotherapy
then led the first successful clinical trials of CD19-targeted CAR-T cells, achieving durable remissions in patients with chronic lymphocytic leukemia (CLL) and acute lymphoblastic leukemia (ALL). His partnership with Novartis culminated in Kymriah becoming the first FDA-approved CAR-T therapy in 2017, marking
More news about: The Tang Prize Foundation
Jun 14, 2026, 21:25 ET 【EHA2026】亞盛醫藥多項臨床數據亮相，彰顯血液腫瘤領域全球創新實力
(PS1713)第一作者：周可樹教授，河南省腫瘤醫院關鍵信息：這是一項基於關鍵II期研究NCT05147467的相關性分析，旨在探索利沙托克拉治療R/R CLL/SLL患者時基線特徵與預後的關係。研究納入77例既往BTKi治療失敗的患者，接受利沙托克拉600mg每日一次治療。在72例可評估患者中，中位PFS為23.9個月，IRC評估ORR為62.5%。進一步分析顯示，TP53突變/del(17p)、複雜核型、基數較大的腫瘤病灶及SF3B1、KIT、BLM、SETD2突變與較差預後相關，其中複雜核型和腫瘤大小是PFS縮短的獨立風險因素。該研究提示，利沙托克拉在BTKi治療失敗後的R/R CLL/SLL患者中具有明確療效，並可通過基線風險特徵進一步識別預後較差人群，為後續風險分層和聯合治療策略提供依據。
More news about: 亞盛醫藥
Jun 14, 2026, 03:15 ET Lilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL
regimen in relapsed or refractory CLL," said Jacob Van Naarden, executive vice president and president of Lilly Oncology. "BRUIN CLL-322 enrolled a mostly covalent BTK inhibitor-pretreated population, ensuring that these results have applicability to the modern CLL treatment landscape where covalent
More news about: Eli Lilly and Company
Jun 12, 2026, 03:00 ET AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results
Final results from the Phase 3 CLL14 trial in previously untreated chronic lymphocytic leukemia (CLL), which was conducted in collaboration with the German CLL Study Group, will be featured in an oral presentation. "The nine-year results from the landmark Phase 3 CLL14 trial affirm venetoclax's enduring
More news about: AbbVie